dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Corti, Francesca |
dc.contributor.author | Infante, Gabriele |
dc.contributor.author | Elez Fernandez, Mª Elena |
dc.contributor.author | Ros Montañá, Fco. Javier |
dc.contributor.author | Fakih, Marwan |
dc.contributor.author | Pietrantonio, Filippo |
dc.contributor.author | Lonardi, Sara |
dc.date.accessioned | 2022-04-22T13:01:39Z |
dc.date.available | 2022-04-22T13:01:39Z |
dc.date.issued | 2021-08 |
dc.identifier.citation | Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, et al. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer. 2021 Aug;9(8):e003370. |
dc.identifier.issn | 2051-1426 |
dc.identifier.uri | https://hdl.handle.net/11351/7373 |
dc.description | Neoplàsies gastrointestinals; Immunoteràpia |
dc.description.sponsorship | The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. |
dc.language.iso | eng |
dc.publisher | BMJ |
dc.relation.ispartofseries | Journal for ImmunoTherapy of Cancer;9(8) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Recte - Càncer - Tractament |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Nomografia (Matemàtica) |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Nomograms |
dc.subject.mesh | Microsatellite Instability |
dc.title | Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/jitc-2021-003370 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | nomogramas |
dc.subject.decs | inestabilidad de microsatélites |
dc.relation.publishversion | http://dx.doi.org/10.1136/jitc-2021-003370 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Pietrantonio F, Corti F] Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Lonardi S] Medical Oncology 3, Istituto Oncologico Veneto IOV-IRCSS, Padua, Italy. [Infante G] Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Elez ME, Ros J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fakih M] Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California, USA |
dc.identifier.pmid | 34429334 |
dc.identifier.wos | 000688528100002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |